Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Cancers|June 27, 2024
Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy InitiationSerena Janho Dit Hreich, Olivier Humbert, Tanguy Pacé-Loscos, et al.
European Urology|July 18, 2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD StudyCora N Sternberg, Daniel Castellano, Johann de Bono, et al.
International Journal of Radiation Oncology, Biology, Physics|October 25, 2025
Stereotactic Versus Standard Tumor Irradiation in Unresectable Locally Advanced Non-small Cell Lung Cancer With Durvalumab Maintenance: A Multicenter Study With Propensity Score MatchingEtienne Cedoz, Antonin Levy, Isabelle Martel-Lafay, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defectsMihaela Aldea, Laurent Lam, Emeline Orillard, et al.
The Lancet. Oncology|September 14, 2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 studyKarim Fizazi, Gero Kramer, Jean-Christophe Eymard, et al.
European Urology|June 4, 2023
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZAEmeline Colomba, Sarah Flora Jonas, Jean-Christophe Eymard, et al.
JAMA Oncology|October 26, 2023
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical TrialStéphane Oudard, Raffaele Ratta, Eric Voog, et al.
European Urology Oncology|August 14, 2024
Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY TrialStephane Oudard, Yohann Tran, Carole Helissey, et al.
European Urology Oncology|March 4, 2024
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate CancerLudovic Bigot, Jonathan Sabio, Loic Poiraudeau, et al.
Virchows Archiv : an International Journal of Pathology|December 31, 2024
EGFR status assessment using reflex testing targeted next-generation sequencing for resected non-squamous non-small cell lung cancerSamantha Goffinet, Christophe Bontoux, Simon Heeke, et al.
Pageof 7